Boston Scientific Corporation is a medical device company that develops, manufactures, and markets minimally invasive technologies for interventional medical specialties. The company operates through two reportable segments: MedSurg and Cardiovascular. The MedSurg segment comprises Endoscopy, Urology, and Neuromodulation business units, offering products for gastrointestinal, pancreaticobiliary, urological, and neurological conditions. The Cardiovascular segment includes Interventional Cardiology and Vascular Therapies, providing solutions for coronary, peripheral, and venous diseases. Key product lines include the SpyGlass single-use scope, Orbera intragastric balloon, GreenLight XPS laser system, WaveWriter Alpha spinal cord stimulator, SYNERGY everolimus-eluting stent, and AngioJet thrombectomy system. The company serves physicians and healthcare systems globally, with commercial representation in numerous countries. Recent acquisitions include Bolt Medical, SoniVie, and a pending acquisition of Penumbra, Inc. to expand its thrombectomy portfolio.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage bostonscientific.com
Sector Healthcare IR page investors.bostonscientific.com
Tags
endoscopy, urology, neuromodulation, interventional cardiology, vascular therapies, spinal cord stimulation, thrombectomy, drug-eluting stents, intravascular imaging, minimally invasive surgery, Resolution 360, MANTIS Clips, WallFlex Biliary Stent Systems, AXIOS Stents, SpyGlass, EXALT Model D, OverStitch, Orbera, LithoVue, Lumenis Pulse, GreenLight XPS, Rezūm, AMS 700, TENACIO, AMS 800, SpaceOAR, Axonics, Bulkamid, WaveWriter Alpha, Intracept, G4 Generator, Vercise Genus, OptiCross, AVVIGO+, ROTAPRO, WOLVERINE, SYNERGY, AGENT, Eluvia, Ranger, AngioJet, EKOS, Varithena, Bolt Medical, SoniVie, TIVUS, Penumbra, Lightning Bolt, Lightning Flash
Press page —

Metrics

Valuation  
Market cap $ 63.27B
Market cap (USD) $ 63.27B
P/E 18.50
PEG 0.28
P/BV 2.47
P/S 3.00
P/OCF 14.94
P/FCF 18.99
Dividend yield —
Turnover / mcap —
Returns  
ROE 12.6%
ROI 8.1%
ROIC 8.7%
Profit margin 14.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 65.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 46.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 41
Quality score 55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 20.074B 16.747B 14.24B 12.682B 11.888B 9.913B 10.735B 9.823B 9.048B 9.076B 8.068B 7.462B 7.143B 7.249B 7.622B 7.806B 8.188B 8.05B 8.357B 7.821B 6.283B 5.624B 3.476B 2.919B 2.673B 2.664B
Net profit 2.892B 1.846B 1.592B 698M 1.041B -82M 4.7B 1.671B 104M 347M -239M -119M -121M -4.068B 441M -1.065B -1.025B -2.036B -495M -3.577B 628M 1.062B 472M 373M -54M 373M
Free cash flow 3.658B 2.645B 1.792B 938M 1.316B 1.132B 1.375B -6M 1.107B 596M 353M 1.01B 837M 1.034B 704M 53M 523M — — — — — 599M 624M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 95.35 89.32 57.81 46.27 42.48 35.95 45.22 35.34 24.79 21.63 18.44 13.25 12.02 5.73 5.34 7.57 9 7.38 12.62 15.52 — — — — — —
Price performance 12m 0.07 0.55 0.25 0.09 0.18 -0.2 0.28 0.43 0.15 0.17 0.39 0.1 1.1 0.07 -0.29 -0.16 0.22 -0.42 -0.19 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.47B 1.55B 1.61B 1.83B 1.53B 1.78B 1.97B 2.23B 2.56B 2.93B
↳ YoY growth +15.5% +5.2% +3.9% +13.7% -16.2% +16.1% +10.8% +13.1% +14.8% +14.4%
↳ 5y CAGR +3.4% +4.9% +4.2% +9.1% +3.7% +3.8% +4.9% +6.7% +7.0% +13.8%
Borrowings, current (USD) 250M 1.8B 2.25B 1.42B 13M 261M 20M 531M 1.78B 299M
Borrowings, non-current (USD) 5.42B 3.82B 4.8B 8.59B 9.13B 8.8B 8.92B 8.57B 8.97B 11.1B
Lease liabilities (USD) — — 0.00 343M 401M 389M 408M 466M 482M 659M
Cash and deposits (USD) 196M 188M 146M 217M 1.73B 1.93B 928M 865M 414M 1.97B
Intangible assets (USD) 5.88B 5.84B 6.37B 7.89B 5.92B 6.12B 5.9B 6B 6.68B 7.02B
Right-of-use assets (USD) — 0.00 0.00 336M 458M 435M 386M 439M 449M 465M
Net debt (borrowings + leases - cash) (USD) 5.47B 5.43B 6.91B 10.1B 7.41B 7.53B 8.42B 8.7B 10.8B 10.1B
Cash flow detail
Operating cash flow (USD) 972M 1.43B 310M 1.84B 1.51B 1.87B 1.53B 2.5B 3.44B 4.53B
Purchases of property, plant and equipment (USD) -376M -319M -316M -461M -376M -554M -588M -711M -790M -876M
Change in receivables (cash effect) (USD) -216M -30M -110M -130M 335M -279M -220M -238M -351M -269M
Change in inventories (cash effect) (USD) 40M -107M -83M -290M -65M -346M -321M -660M -228M -188M
Change in payables (cash effect) (USD) 553M 195M -631M 111M 88M 408M -255M 118M 243M 296M
Dividends paid (cash effect) (USD) — — 0.00 0.00 -28M -55M -55M -28M 0.00 —
Share buybacks (cash effect) (USD) 0.00 — 0.00 0.00 -535M 0.00 0.00 — — —
Interest paid (cash effect) (USD) -233M -235M -262M -449M -359M -338M -450M -259M -250M -319M
Income taxes paid (cash effect) (USD) -94M -42M -1.04B -242M -207M -302M -662M -512M -656M -561M
Share-based compensation (USD) 116M 127M 140M 157M 170M 194M 220M 233M 266M 299M
Operating cash flow before change in receivables (USD) 1.19B 1.46B 420M 1.97B 1.17B 2.15B 1.75B 2.74B 3.79B 4.8B
Free cash flow (OCF - PPE - intangibles) (USD) 596M 1.11B -6M 1.38B 1.13B 1.32B 938M 1.79B 2.65B 3.66B
Income detail
Research and development expense (USD) 920M 997M 1.11B 1.17B 1.14B 1.2B 1.32B 1.41B 1.62B 2.05B
↳ 5y CAGR +0.6% +2.4% +5.3% +7.5% +5.5% +5.5% +5.8% +4.9% +6.6% +12.4%
Total comprehensive income (USD) 260M 45M 1.76B 4.94B -145M 1.1B 704M 1.36B 2.06B 2.02B
Comprehensive income to owners (USD) — — — — — 1.1B 704M 1.37B 2.08B 2.01B
Provision for credit losses (USD) — — 19M 23M 49M 28M 35M 50M 41M 56M
Credit cost ratio (credit losses / average receivables) (%) — — 1.2% 1.3% 2.9% 1.7% 1.9% 2.4% 1.7% 2.0%
Reported Feb 23, 2017 Feb 25, 2020 Feb 23, 2021 Feb 23, 2021 May 6, 2021 Feb 20, 2024 Feb 20, 2024 Feb 20, 2024 Feb 18, 2025 Feb 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

(i) 2027 Annual Bonus Plan

On November 17, 2026, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) approved the Company’s 2027 Annual Bonus Plan effective for the performance year of January 1, 2027 through December 31, 2027 (the “2027 Annual Bonus Plan”).

As part of the Company’s overall compensation program, the 2027 Annual Bonus Plan provides an annual cash incentive opportunity for eligible exempt and nonexempt indirect labor or equivalent personnel (including the Company’s named executive officers meeting the eligibility criteria) based on the achievement of certain performance metrics.

Diabetic peripheral neuropathy: when diabetes turns painful Bull 0 Bear 0 Product/operations

Nov 3, 2026

Read more

Diabetic peripheral neuropathy can cause burning pain, numbness and tingling in the feet and legs, making everyday activities challenging for people living with diabetes.

Diabetic peripheral neuropathy can cause burning pain, numbness and tingling in the feet and legs, making everyday activities challenging for people living with diabetes.

More than 40 million Americans live with diabetes , and for many, managing blood sugar is only one part of the daily challenge.  

As many as half of people with diabetes may develop diabetic peripheral neuropathy (DPN), a form of nerve damage that can cause burning pain, numbness and tingling, most often in the feet and legs.  

“For some patients, the pain can be so severe that they cannot sleep, wear shoes and socks or even tolerate a bedsheet touching their feet,” said Scott Kreiner, M.D., chief medical officer for Boston Scientific's Neuromodulation division. “Simple activities that most people take for granted can become a constant challenge.” 

Today, a proven therapy for meaningful pain relief is offering DPN patients a different treatment option: spinal cord stimulation (SCS). 

Understanding the different forms of diabetic neuropathy 

Diabetic neuropathy is not a single condition. It is a group of nerve disorders that can affect different parts of the body. The most common form is peripheral neuropathy, which typically causes pain and numbness and tingling in the feet and legs.  

For many people with diabetes, peripheral neuropathy is the form that most directly interferes with daily life.  

That certainly was the case for Tamara, a teacher who lived with chronic pain for a decade. During that time, she tried to maintain an upbeat attitude around her students but the pain in her legs and feet made that difficult. 

“My quality of life was just gone,” Tamara said. 

"Meaningful” results with spinal cord stimulation 

Because DPN results from nerve damage associated with prolonged high blood sugar, clinicians often advise patients to eat healthy and exercise to manage their glucose levels. But staying active can be challenging when everyday actions, such as putting on socks or tying shoes, can cause debilitating pain. Medications may help relieve the pain, but determining an effective dose can take months, and side effects such as drowsiness, dizziness, headaches and nausea are common. 

Spinal cord stimulation offers another treatment option. 

Long used to treat other forms of chronic pain such as chronic back pain, SCS is an approved treatment option for painful diabetic peripheral neuropathy. Boston Scientific's WaveWriter Alpha™ Spinal Cord Stimulator System uses an implanted pulse generator that delivers mild electrical pulses to interrupt pain signals before they reach the brain. Physicians can personalize stimulation settings to each patient's needs, helping tailor therapy to fluctuations in pain over time.  

Clinical data supporting the use of Boston Scientific's SCS therapy in people living with DPN have demonstrated meaningful outcomes in clinical trials. In one study, 81% of patients reported at least a 50% reduction in pain at two years following treatment with the WaveWriter Alpha System. Other studies have shown improvements in measures associated with everyday function, including the ability to sit, stand and sleep more comfortably.  

“When we trial spinal cord stimulation in patients with diabetic peripheral neuropathy, they often describe the results as meaningful compared with other treatments they have tried,” Kreiner said. “It has been rewarding to have another option for people who have gone back to their doctors repeatedly without finding relief.” 

Feeling good and baking cookies 

For Tamara, treating her diabetic neuropathy with spinal cord stimulation has meant more good days. She’s even started baking cookies again, something she says she couldn’t do when her DPN was at its worst. 

“I wish I would have made the decision sooner,” she said. “To have days where I can wake up and go, and feel good and be happy, has given me my life back.” 

Learn more about Boston Scientific's innovative approaches to treating chronic pain at Pain.com.   

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary. Talk to your doctor about the risks and benefits of spinal cord stimulation and if it is an option for you.   

Top

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.


©2026 Boston Scientific Corporation or its affiliates. All rights reserved.

(opens in a new window)

Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens

MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire / -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device. The study evaluated two single-drug regimens as alternatives to dual anti-platelet therapy (DAPT) following implantation of the device in patients with non-valvular atrial fibrillation (NVAF). Key results were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2026, the annual scientific symposium of the Cardiovascular Research Foundation® (CRF®) and simultaneously published in JAMA .

The WATCHMAN FLX Pro device used in the trial is intended to protect against strokes caused by blood clots that form in the left atrial appendage (LAA) in people with NVAF who need an alternative to long-term blood thinners, and includes HEMOCOAT Technology™, which is designed to enable more controlled, faster healing following implantation. The SIMPLAAFY trial is assessing whether the device, with the addition of HEMOCOAT, may continue to offer similar rates of stroke protection and reduce early bleeding when paired with less-intensive post-implant regimens, and will follow patients through 12 months.

"For patients with NVAF who undergo an LAAC procedure, balancing short-term bleeding risk with the need to maintain stroke protection during post-procedure healing is critical," said Saibal Kar, M.D., study co-chair and director, Structural Heart Disease Interventions and Clinical Research, Los Robles Health System.* "The findings from the SIMPLAAFY trial are encouraging and highlight the potential to meaningfully simplify post-procedure care and reduce medication burden for patients following WATCHMAN FLX Pro implantation."

The study randomized 1,857 patients across 86 clinical study sites in the U.S. to a post-implant regimen of aspirin alone for the duration of the trial or reduced-dose non-vitamin K antagonist oral anticoagulant (NOAC) for the first three months followed by aspirin only or a DAPT regimen of aspirin and clopidogrel antiplatelet medication for the first six months, followed by aspirin only. At six months, data demonstrated that the aspirin alone and reduced-dose NOAC alone regimens each achieved noninferiority to DAPT, with patients on these regimens experiencing less bleeding and equivalent ischemic stroke rates to DAPT (0.7%). Additionally, imaging at 45 days also showed the rate of device-related thrombus, or clotting, was lowest in the patients on a reduced-dose NOAC compared to DAPT (0.9% vs. 3.4%; P=0.01).

"Innovation in LAAC extends beyond device technology to advancing the therapy through improved care delivery and an enhanced experience for physicians and patients," said Brad Sutton, M.D., chief medical officer, Atrial Fibrillation Solutions, Boston Scientific. "The SIMPLAAFY trial provides valuable clinical evidence that can help physicians make more informed decisions about post-implant care and tailor treatment to individual patient needs. Together with advancements like HEMOCOAT Technology, these findings represent meaningful progress toward simplifying treatment and advancing care for patients with atrial fibrillation."

With more than two decades of clinical evidence, the WATCHMAN implant has helped reduce stroke risk for more than 800,000 patients worldwide. The current-generation WATCHMAN FLX Pro device was approved by the U.S. Food and Drug Administration in 2023. Enrollment in the Elite AF trial, evaluating the safety and efficacy of the next-generation WATCHMAN Elite™ LAAC Device, commenced in 2026.

Prompts

Boston Scientific Corporation (ticker BSX), listed in United States.

Company History

Date Change Detail
Aug 7, 2024 Acquired Acquired Silk Road Medical Inc (CIK 1397702). Its filings from before the deal are on its own company page, not shown here.
Mar 30, 2023 Acquired Acquired Apollo Endosurgery, Inc. (CIK 1251769). Its filings from before the deal are on its own company page, not shown here.
Nov 7, 2016 Acquired Acquired Endochoice Holdings, Inc. (CIK 1623919). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Boston Scientific Corporation

ETF Weight in ETF Shares Market value As of
DAK 2.09% 20,376 $ 880K Nov 18, 2026
GDOC 1.54% 6,257 $ 302.213K Aug 31, 2026
RUNN 1.48% 127,172 $ 6.142M Aug 31, 2026
CGMM 1.38% 1,147,693 $ 50.143M Nov 16, 2026
HRTS 1.32% 15,214 $ 734.836K Aug 31, 2026
FMED 1.14% 12,185 $ 588.536K Aug 31, 2026
MFSV 0.97% 121,012 $ 5.845M Aug 31, 2026
CGGO 0.95% 2,553,880 $ 111.579M Nov 16, 2026
KNO 0.88% 9,340 $ 398.631K Jun 30, 2026
DWSH short -0.78% -1,121 $ -48.237K Nov 17, 2026
PSET 0.74% 5,002 $ 213.485K Jun 30, 2026
ESLG 0.73% 3,643 $ 170.237K Jul 31, 2026
FBCV 0.73% 27,678 $ 1.293M Jul 31, 2026
FWD 0.72% 476,293 $ 23.005M Aug 31, 2026
MMID 0.65% 4,893 $ 236.332K Aug 31, 2026
ESLV 0.51% 1,571 $ 73.413K Jul 31, 2026
TLG 0.50% 15,829 $ 675.582K Jun 30, 2026
ESUM 0.47% 18,511 $ 865.019K Jul 31, 2026
RCGE 0.47% 10,867 $ 470K Nov 18, 2026
VFVA 0.46% 91,846 $ 4.436M Aug 31, 2026
THMZ 0.45% 5,654 $ 241.313K Jun 30, 2026
FFLC 0.41% 105,928 $ 4.95M Jul 31, 2026
CLSE short -0.39% -73,011 $ -3.526M Aug 31, 2026
EVNT short -0.39% -1,057 $ -51.053K Aug 31, 2026
BLCR 0.37% 816,308 $ 35.664M Nov 16, 2026
JAVA 0.37% 635,865 $ 27.361M Nov 17, 2026
JDOC 0.34% 792 $ 34.08K Nov 17, 2026
BALQ 0.33% 3,208 $ 140.158K Nov 16, 2026
EHLS short -0.33% -4,032 $ -176.158K Nov 17, 2026
BAMG 0.32% 8,413 $ 406.348K Aug 31, 2026
CAPE 0.29% 16,211 $ 691.885K Jun 30, 2026
ENHU 0.29% 629 $ 27.481K Nov 16, 2026
LVDS 0.29% 8,072 $ 347.338K Nov 17, 2026
TACU 0.25% 1,058 $ 46.224K Nov 17, 2026
BALI 0.24% 85,570 $ 3.739M Nov 16, 2026
OEI 0.23% 2,327 $ 108.741K Jul 31, 2026
CDX 0.23% 13,204.6825 $ 568.197K Nov 17, 2026
GSPY 0.23% 37,004 $ 1.617M Nov 17, 2026
LQAI 0.22% 112 $ 4,950.40 Nov 12, 2026
MFSG 0.21% 16,663 $ 804.823K Aug 31, 2026
AIVL 0.20% 19,733 $ 842.204K Jun 30, 2026
DFUV 0.20% 713,544 $ 31.539M Nov 12, 2026
GOP 0.19% 3,756 $ 164.1K Nov 17, 2026
THRO 0.18% 426,589 $ 18.638M Nov 16, 2026
GVLU 0.18% 10,529 $ 460.012K Nov 17, 2026
FTLS short -0.17% -99,213 $ 0.00 Nov 16, 2026
MPLY 0.17% 569 $ 26.589K Jul 31, 2026
VSLU 0.16% 20,848 $ 889.793K Jun 30, 2026
XMAG 0.15% 7,347 $ 324.737K Nov 13, 2026
MODL 0.13% 31,939 $ 1.363M Jun 30, 2026
ACVF 0.13% 4,245 $ 198.369K Jul 31, 2026
DYNF 0.13% 1,263,558 $ 55.205M Nov 16, 2026
DFLV 0.13% 222,619 $ 9.84M Nov 12, 2026
SFTY 0.11% 17,255 $ 833.417K Aug 31, 2026
STOX 0.10% 4,868 $ 235.124K Aug 31, 2026
VOXP 0.10% 126 $ 5,887.98 Jul 31, 2026
GEW 0.10% 2,934 $ 141.712K Aug 31, 2026
JUSA 0.10% 20,874 $ 898.208K Nov 17, 2026
APUE 0.10% 49,897 $ 2.41M Aug 31, 2026
GDE 0.09% 9,082 $ 438.661K Aug 31, 2026
NTSX 0.09% 27,434 $ 1.171M Jun 30, 2026
HCMT 0.09% 10,340 $ 483.188K Jul 31, 2026
HEQQ 0.08% 572 $ 24.613K Nov 17, 2026
NTSD 0.07% 621 $ 26.504K Jun 30, 2026
AVSU 0.07% 7,255 $ 316.971K Nov 16, 2026
MSLC 0.07% 56,965 $ 2.751M Aug 31, 2026
DCOR 0.05% 535,443 $ 23.667M Nov 12, 2026
WSGE 0.05% 704 $ 30.293K Nov 18, 2026
DFUS 0.05% 227,970 $ 10.076M Nov 12, 2026
AVUS 0.04% 140,902 $ 6.156M Nov 16, 2026
AVLC 0.04% 12,736 $ 556.436K Nov 16, 2026
LCTU 0.04% 10,174 $ 444.502K Nov 16, 2026
THEQ 0.04% 310 $ 13.544K Nov 17, 2026
DFAU 0.03% 100,297 $ 4.433M Nov 12, 2026
CSHP 0.03% 2,949 $ 128.842K Nov 16, 2026
DXUV 0.03% 38,951 $ 1.722M Nov 12, 2026
DFAC 0.02% 477,630 $ 21.111M Nov 12, 2026
LGDX 0.02% 694 $ 30.321K Nov 17, 2026
FELG 0.02% 23,809 $ 1.016M Jun 30, 2026
FELC 0.01% 17,175 $ 733.029K Jun 30, 2026
DFSU 0.01% 4,165 $ 184.093K Nov 12, 2026
NPFE 0.00% 24 $ 1,121.52 Jul 31, 2026
EBI 0.00% 3 $ 144.90 Aug 31, 2026
CORO 0.00% 914 $ 39.931K Nov 16, 2026